QIAGEN Expands Bioinformatics Leadership with New Data Center in Asia-Pacific
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has officially opened a new data center in Melbourne, Australia, reinforcing its leadership in global bioinformatics, particularly in the Asia-Pacific region. This new facility is part of QIAGEN’s ongoing strategy to enhance its bioinformatics data infrastructure, supporting its efforts to expand the use of bioinformatics products across Australia, New Zealand, New Guinea, and the surrounding islands.
This Melbourne data center is the latest addition to QIAGEN’s global network, which already includes seven other strategically located data centers in the United States, United Kingdom, Denmark, Turkey, South Korea, Japan, and China. The expansion in the Asia-Pacific region is a direct response to the increasing demand for bioinformatics solutions in genomic testing laboratories and healthcare applications. With this investment, QIAGEN ensures that it can offer robust, local data hosting solutions while meeting the region’s evolving regulatory and privacy requirements.
The Melbourne data center is designed to help local genomic testing labs securely store sensitive data while complying with Australian privacy and health data regulations. This addition highlights QIAGEN’s ongoing commitment to delivering tailored bioinformatics solutions that support the clinical and diagnostic services provided by healthcare professionals in the region. By supporting local data hosting, QIAGEN is helping to meet the growing needs of the region’s rapidly expanding genomics industry.
“Opening this new data center strengthens our ability to serve the Australian market and the broader Australia/Asia-Pacific region,” said Dominic John, Vice President of QIAGEN Digital Insights. “This facility will allow diagnostic labs to confidently provide clinical next-generation sequencing (NGS) testing services, ensuring compliance with increasingly stringent data sovereignty laws. With eight global data centers now operational, we can continue to provide high levels of data security, compliance, and operational excellence worldwide.”
The Asia-Pacific region, with its diverse healthcare systems and regulatory environments, presents unique challenges and opportunities for bioinformatics. The establishment of the Melbourne data center is strategically positioned to support QIAGEN’s ability to meet these challenges head-on. It ensures that clinical testing services, such as next-generation sequencing, can be performed with the utmost precision and in compliance with local data protection laws. The facility also ensures that Australian labs can access QIAGEN’s advanced bioinformatics tools and software, streamlining their workflows while maintaining the highest standards of data privacy and security.
Next-generation sequencing (NGS) continues to evolve, and QIAGEN is at the forefront of delivering bioinformatics solutions that help labs and researchers harness the full potential of genomics. The company’s robust suite of bioinformatics tools and knowledge bases supports genomic analysis, personalized medicine, and precision healthcare applications. The Melbourne data center represents a significant step forward in QIAGEN’s ability to provide real-time, secure access to cutting-edge genomic analysis and insights for clinical laboratories and healthcare providers in the region.
As the use of NGS expands, QIAGEN’s bioinformatics solutions empower clinical labs to interpret complex genomic data efficiently, helping to accelerate the discovery of biomarkers, personalized therapies, and improved patient outcomes. By providing tools that turn raw biological data into clear, actionable insights, QIAGEN is helping to shape the future of healthcare in Australia and across the broader Asia-Pacific region.
With more than 25 years of experience in the industry, QIAGEN Digital Insights (QDI) serves over 90,000 users worldwide and has profiled more than 4 million patient cases. QIAGEN’s vast experience and leadership in the field make it a trusted partner for researchers, clinicians, and healthcare providers. By continuously developing intuitive, scalable bioinformatics solutions, QIAGEN aims to accelerate breakthroughs in science and healthcare.
QIAGEN’s bioinformatics platform is helping to unlock new discoveries in genomics, advancing precision medicine and improving clinical decision-making. The company’s solutions are used by healthcare professionals to interpret genetic data for a variety of applications, including cancer research, genetic disease diagnostics, and personalized treatment planning.
In addition to supporting local labs in Australia, the Melbourne data center will also play a critical role in advancing QIAGEN’s mission to expand its reach across the Asia-Pacific region. The region’s rapidly growing healthcare and life sciences sectors are increasingly turning to advanced genomic testing to drive innovation in disease diagnosis and treatment. By establishing a local presence, QIAGEN is well-positioned to meet the region’s needs for secure, compliant, and efficient bioinformatics solutions.
About QIAGEN
QIAGEN N.V. is a global leader in providing Sample to Insight solutions. The company helps customers extract and analyze DNA, RNA, and proteins from biological samples, enabling actionable insights in life sciences and healthcare applications. QIAGEN’s technologies include tools for isolating biomolecules, preparing samples for analysis, and interpreting the resulting data. With over 500,000 customers across a wide range of industries, QIAGEN serves researchers, pharmaceutical companies, and healthcare providers worldwide. The company employs more than 5,700 people across 35 locations globally as of December 31, 2024.
